| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Shz-1 does not have a specific protein target in the classical sense of a receptor or enzyme inhibitor. Instead, it functions as a cardiogenic molecule that activates cardiac-specific gene programs. It induces the expression of early cardiac genes, such as sarcomeric tropomyosin and Nkx2.5, in pluripotent stem cells.
|
|---|---|
| ln Vitro |
In vitro, Shz-1 induces the expression of various cardiac-specific genes, including sarcomeric tropomyosin, in P19CL6 cells. It also induces Nkx2.5 expression and activates the axolotl TPM4 promoter-driven expression in C2C12 cells. These activities demonstrate its potency in promoting a cardiac phenotype in stem cells at low micromolar concentrations.
|
| ln Vivo |
In vivo, Shz-1 has been shown to drive the differentiation of human peripheral blood mononuclear cells (M-PBMCs) toward a cardiac phenotype. In animal models, such as the cryo-injured rat heart, Shz-1 treated cells have demonstrated the ability to enhance myocardial regenerative repair. This highlights its potential in regenerative medicine research for promoting cardiac repair.
|
| Enzyme Assay |
General protocols for studying Shz-1 involve treating stem cells (e.g., P19CL6, mouse embryonic stem cells, or human M-PBMCs) in culture. The compound is typically added to the culture medium at low micromolar concentrations. After a defined treatment period, cells are harvested for analysis. Gene expression is assessed via RT-qPCR and protein expression via Western blot or immunocytochemistry.
|
| Cell Assay |
In cell-based assays, Shz-1 is used to induce cardiac differentiation in various stem and progenitor cell lines. Following treatment, the expression of cardiac markers (e.g., tropomyosin, Nkx2.5) is measured. Functional assays, such as measuring spontaneous beating in cardiomyocyte-like cells, can also be performed to confirm the acquisition of a cardiac phenotype.
|
| Animal Protocol |
In vivo protocols involve harvesting and treating cells (e.g., M-PBMCs) with Shz-1 ex vivo before transplanting them into animal models of cardiac injury. For example, in cryo-injured rat hearts, the transplantation of Shz-1-treated cells is followed by assessment of myocardial repair and function. The compound can also be administered in vivo to investigate its direct effects on cardiac regeneration.
|
| ADME/Pharmacokinetics |
Shz-1 has a molecular weight of 355.21 g/mol and a molecular formula of C13H11BrN2O3S. It is a crystalline solid soluble in DMF, DMSO, and ethanol (30 mg/mL). It has UV absorbance maxima at 219, 275, and 329 nm. For storage, it should be kept at -20°C. It is cell-permeable.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Shz-1 is primarily defined by its research use. It is not intended for human or veterinary use. As a potent cardiogenic agent, its effects are specific to inducing cardiac differentiation in stem cells. Standard laboratory safety precautions should be followed when handling this compound. Detailed toxicological data are not widely published, as it is exclusively a research tool.
|
| Additional Infomation |
Shz-1 (CAS 326886-05-9) is a potent cardiogenic small molecule used in stem cell research to induce cardiac differentiation. It activates cardiac-specific gene programs in pluripotent and embryonic stem cells and has shown promise in enhancing myocardial repair in preclinical models. It is a valuable research tool for studying cardiac development and regenerative medicine. It is not approved for clinical use.
|
| Molecular Formula |
C13H11BRN2O3S
|
|---|---|
| Molecular Weight |
355.207041025162
|
| Exact Mass |
353.967
|
| CAS # |
326886-05-9
|
| PubChem CID |
135446537
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
503.9±60.0 °C at 760 mmHg
|
| Flash Point |
258.5±32.9 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.648
|
| LogP |
4.07
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
429
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)S(=O)(=O)N/N=C/C2=CC(=CC=C2O)Br
|
| InChi Key |
OEMCLQLAWYKPRK-OQLLNIDSSA-N
|
| InChi Code |
InChI=1S/C13H11BrN2O3S/c14-11-6-7-13(17)10(8-11)9-15-16-20(18,19)12-4-2-1-3-5-12/h1-9,16-17H/b15-9+
|
| Chemical Name |
N-[(E)-(5-bromo-2-hydroxyphenyl)methylideneamino]benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~703.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8152 mL | 14.0762 mL | 28.1524 mL | |
| 5 mM | 0.5630 mL | 2.8152 mL | 5.6305 mL | |
| 10 mM | 0.2815 mL | 1.4076 mL | 2.8152 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
